Stock 300676 BGI GENOMICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BGI Genomics Co., Ltd.

Equities

300676

CNE100003449

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
39.74 CNY +2.11% Intraday chart for BGI Genomics Co., Ltd. +4.36% -17.21%
Apr. 26 BGI Genomics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 15 BGI Genomics Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 24,006 27,487 50,923 35,990 21,188 19,676
Enterprise Value (EV) 1 22,431 26,335 46,771 28,192 14,979 14,555
P/E ratio 61.9 x 99.5 x 24.6 x 24.7 x 26.4 x 213 x
Yield 0.5% 0.15% 0.27% 0.4% 1.93% 0.21%
Capitalization / Revenue 9.46 x 9.82 x 6.06 x 5.32 x 3.01 x 4.52 x
EV / Revenue 8.84 x 9.4 x 5.57 x 4.17 x 2.13 x 3.35 x
EV / EBITDA 42 x 53.1 x 16.2 x 14.4 x 12.8 x 30.6 x
EV / FCF -31.9 x 125 x 16.9 x 15.4 x -23.3 x -39.1 x
FCF Yield -3.14% 0.8% 5.92% 6.49% -4.28% -2.56%
Price to Book 5.76 x 6.37 x 8.64 x 3.86 x 2.1 x 1.85 x
Nbr of stocks (in thousands) 400,100 400,100 396,100 409,914 409,914 409,914
Reference price 2 60.00 68.70 128.6 87.80 51.69 48.00
Announcement Date 4/24/19 4/24/20 4/25/21 4/22/22 3/30/23 4/12/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,536 2,800 8,397 6,766 7,046 4,350
EBITDA 1 534.5 496.2 2,891 1,951 1,172 475.9
EBIT 1 366.9 257.6 2,592 1,680 826.8 124.2
Operating Margin 14.46% 9.2% 30.86% 24.83% 11.73% 2.86%
Earnings before Tax (EBT) 1 474.9 328.2 2,442 1,746 1,007 115.5
Net income 1 386.6 276.3 2,090 1,462 802.9 92.9
Net margin 15.24% 9.87% 24.89% 21.6% 11.4% 2.14%
EPS 2 0.9700 0.6907 5.235 3.550 1.957 0.2253
Free Cash Flow 1 -703.6 210.8 2,767 1,829 -641.5 -372.3
FCF margin -27.74% 7.53% 32.95% 27.03% -9.1% -8.56%
FCF Conversion (EBITDA) - 42.49% 95.7% 93.73% - -
FCF Conversion (Net income) - 76.3% 132.37% 125.15% - -
Dividend per Share 2 0.3000 0.1010 0.3500 0.3500 1.000 0.1000
Announcement Date 4/24/19 4/24/20 4/25/21 4/22/22 3/30/23 4/12/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,575 1,152 4,152 7,798 6,209 5,121
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -704 211 2,767 1,829 -642 -372
ROE (net income / shareholders' equity) 9.58% 6.44% 40.3% 19.1% 8.23% 0.93%
ROA (Net income/ Total Assets) 4.43% 2.89% 18.9% 8.25% 3.61% 0.55%
Assets 1 8,738 9,578 11,036 17,710 22,243 16,757
Book Value Per Share 2 10.40 10.80 14.90 22.70 24.60 26.00
Cash Flow per Share 2 2.670 1.840 13.70 16.10 12.60 12.50
Capex 1 678 626 301 384 1,267 1,236
Capex / Sales 26.74% 22.37% 3.59% 5.67% 17.98% 28.43%
Announcement Date 4/24/19 4/24/20 4/25/21 4/22/22 3/30/23 4/12/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

1st Jan change Capi.
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-17.21% 2.08B
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.45% 10.82B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+43.17% 3.25B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-35.86% 2.11B
VERACYTE, INC. Stock Veracyte, Inc.
-29.81% 1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+17.56% 1.02B
SEEGENE, INC. Stock Seegene, Inc.
-4.37% 733M
CAREDX, INC Stock CareDx, Inc
-37.00% 391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-46.94% 377M
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
+13.32% 332M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. 300676 Stock
  4. Financials BGI Genomics Co., Ltd.